<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
<head>
<meta http-equiv="Content-Type" content=
"text/html; charset=utf-8" /><!-- AppResources meta begin -->

<script type="text/javascript">
//<![CDATA[
var ncbi_startTime = new Date();
//]]>
</script><!-- AppResources meta end -->
<!-- TemplateResources meta begin -->
<meta name="paf_template" content="" />
<!-- TemplateResources meta end -->
<!-- Logger begin -->
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_pdid" content="article" />
<meta name="ncbi_acc" content="" />
<meta name="ncbi_domain" content="brjclinpharm" />
<meta name="ncbi_report" content="record" />
<meta name="ncbi_type" content="fulltext" />
<meta name="ncbi_objectid" content="" />
<meta name="ncbi_pcid" content="/articles/PMC2014477/" />
<meta name="ncbi_app" content="pmc" /><!-- Logger end -->
<title>Inhibitory effects of verapamil and diltiazem on simvastatin
metabolism in human liver microsomes</title>
<!-- AppResources external_resources begin -->
<link rel="stylesheet" href="/core/jig/1.14.4/css/jig.min.css" />
<script type="text/javascript" src=
"/core/jig/1.14.4/js/jig.min.js">
</script><!-- AppResources external_resources end -->
<!-- Page meta begin -->
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" />
<link rel="canonical" href="/pmc/articles/PMC2014477/" />
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" />
<meta name="citation_journal_title" content=
"British Journal of Clinical Pharmacology" />
<meta name="citation_title" content=
"Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes" />
<meta name="citation_authors" content=
"Karen Rowland Yeo, Wilfred W Yeo" />
<meta name="citation_date" content="May 2001" />
<meta name="citation_issue" content="5" />
<meta name="citation_volume" content="51" />
<meta name="citation_firstpage" content="461" />
<meta name="citation_doi" content=
"10.1046/j.1365-2125.2001.01386.x" />
<meta name="citation_abstract_html_url" content=
"/pmc/articles/PMC2014477/?report=abstract" />
<meta name="citation_pmid" content="11422004" />
<meta name="DC.Title" content=
"Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes" />
<meta name="DC.Type" content="Text" />
<meta name="DC.Publisher" content="Wiley-Blackwell" />
<meta name="DC.Contributor" content="Karen Rowland Yeo" />
<meta name="DC.Contributor" content="Wilfred W Yeo" />
<meta name="DC.Date" content="2001 May" />
<meta name="DC.Identifier" content=
"10.1046/j.1365-2125.2001.01386.x" />
<meta name="DC.Language" content="en" />
<meta property="og:title" content=
"Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes" />
<meta property="og:type" content="article" />
<meta property="og:description" content=
"To determine the effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes and to compare their inhibitory potencies and CYP3A4 inactivation parameters with those reported previously for mibefradil.Simvastatin metabolism was ..." />
<meta property="og:url" content=
"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2014477/" />
<meta property="og:site_name" content="PubMed Central (PMC)" />
<meta property="og:image" content=
"http://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png" />
<meta name="twitter:card" content="summary" />
<meta name="twitter:site" content="@ncbi" />
<link rel="stylesheet" href="/corehtml/pmc/css/3.4/pmc.min.css"
type="text/css" />
<link rel="stylesheet" href=
"/corehtml/pmc/css/3.4/pmc_extras_prnt.min.css" type="text/css"
media="print" />
<script type="text/javascript" src=
"/corehtml/pmc/js/common.min.js">
//<![CDATA[
//
//]]>
</script>
<script type="text/javascript" src=
"/corehtml/pmc/js/NcbiTagServer.min.js">
//<![CDATA[
//
//]]>
</script>
<meta name="citationexporter" content=
"backend:'/pmc/utils/ctxp/'" />
<script type="text/javascript" src=
"/corehtml/pmc/ctxp/jquery.citationexporter.js">
//<![CDATA[
//
//]]>
</script>
<link rel="stylesheet" href=
"/corehtml/pmc/ctxp/citationexporter.css" type="text/css" />
<script type="text/javascript" src=
"/core/mathjax/2.6.1/MathJax.js?config=/corehtml/pmc/js/mathjax-config-classic.3.4.js">
</script>
<script type="text/javascript" src=
"/corehtml/pmc/js/large-obj-scrollbars.min.js">
</script>
<script type="text/javascript">
//<![CDATA[
window.name="mainwindow";
//]]>
</script>
<style type="text/css">
/*<![CDATA[*/
.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-brjclinpharm.gif);background-size: auto, contain}
/*]]>*/
</style>

<style type="text/css">
/*<![CDATA[*/
.print-view{display:block}
/*]]>*/
</style>

<style type="text/css">
/*<![CDATA[*/
        div.pmc_para_cit li.highlight,
        div.pmc_para_cit li.highlight .one_line_source
        { background: #E0E0E0; }
        a.bibr.highlight { background: #E0E0E0; } 
/*]]>*/
</style>
<link rel="alternate" type="application/epub+zip" href=
"/pmc/articles/PMC2014477/epub/" />
<link rel="alternate" type="application/pdf" href=
"/pmc/articles/PMC2014477/pdf/bcp0051-0461.pdf" />
<!-- Page meta end -->
<link rel="shortcut icon" href=
"//www.ncbi.nlm.nih.gov/favicon.ico" />
<meta name="ncbi_phid" content=
"F4FC4E326FE7CA9100000000007FEBF5" />
<link type="text/css" rel="stylesheet" href=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/css/3852956/3985586/3808861/3734262/3974050/3917732/251717/4048120/3846471/14534/45193/3988413/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3881636/3579733/4062871/12930/3964959/3855473/4047625/3854974/3854955/4076335/4052581/9685/3549676/3609192/3609193/3609213/3395586/3855312.css" />
<link type="text/css" rel="stylesheet" href=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/css/3411343/3882866/3929378.css"
media="print" />
</head>
<body class="article">
<div class="grid">
<div class="col twelve_col nomargin shadow">
<!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
<div class="sysmessages"><noscript>
<p class="nojs"><strong>Warning:</strong> The NCBI web site
requires JavaScript to function. <a href=
"/guide/browsers/#enablejs" title="Learn how to enable JavaScript"
target="_blank">more...</a></p>
</noscript></div>
<!--/.sysmessage-->
<div class="wrap">
<div class="page">
<div class="top">
<div class="universal_header" id="universal_header">
<ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id=
"navcontent">
<li class=
"ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt">
<a class="ui-ncbimenu-link-first" href="/" role="banner" title=
"NCBI Home" id="ncbihome" accesskey="1"><span class=
"offscreen_noflow">NCBI</span><img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/28977"
class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li>
<li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href=
"#maincontent" title="Skip to the content" tabindex="0" accesskey=
"3">Skip to main content</a></li>
<li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href=
"#navcontent" title="Skip to the navigation" tabindex="0"
accesskey="4">Skip to navigation</a></li>
<li id="resource-menu" class=
"topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset">
<a class=
"ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown"
href=
"/static/header_footer_ajax/submenu/#resources">Resources</a></li>
<li id="all-howtos-menu" class=
"topmenu ui-helper-reset ui-ncbimenu-item-first"><a class=
"ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown"
href="/static/header_footer_ajax/submenu/#howto">How To</a></li>
<li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href=
"/guide/browsers/#accesskeys" title="About My NCBI Accesskeys"
tabindex="0" accesskey="0">About NCBI Accesskeys</a></li>
</ul>
<div class="myncbi"><span id="myncbiusername" style=
"display:none"><a href="/account/settings/" id="mnu" title=
"Edit account settings"></a></span><a accesskey="2" href="/myncbi/"
id="myncbi" style="display:none">My NCBI</a><a href="/account/" id=
"sign_in">Sign in to NCBI</a><a href="/account/signout/" id=
"sign_out" style="display:none">Sign Out</a></div>
</div>
<div class="header">
<div class="res_logo">
<h1 class="img_logo"><a href="/pmc/" class=
"pmc_logo offscreen">PMC</a></h1>
<div class="NLMLogo"><a href="http://www.nlm.nih.gov/" title=
"US National Library of Medicine">US National Library of
Medicine</a><br />
<a href="http://www.nih.gov/" title=
"National Institutes of Health">National Institutes of
Health</a></div>
</div>
<div class="search">
<form method="get" action="/pmc/">
<div class="search_form"><label for="database" class=
"offscreen_noflow">Search database</label><select id="database">
<optgroup label="Recent">
<option value="pmc" selected="selected" class="last" data-ac_dict=
"pmc-search-autocomplete">PMC</option>
</optgroup>
<optgroup label="All">
<option value="gquery">All Databases</option>
<option value="assembly">Assembly</option>
<option value="bioproject">BioProject</option>
<option value="biosample">BioSample</option>
<option value="biosystems">BioSystems</option>
<option value="books">Books</option>
<option value="clinvar">ClinVar</option>
<option value="clone">Clone</option>
<option value="cdd">Conserved Domains</option>
<option value="gap">dbGaP</option>
<option value="dbvar">dbVar</option>
<option value="epigenomics">Epigenomics</option>
<option value="nucest">EST</option>
<option value="gene">Gene</option>
<option value="genome">Genome</option>
<option value="gds">GEO DataSets</option>
<option value="geoprofiles">GEO Profiles</option>
<option value="nucgss">GSS</option>
<option value="gtr">GTR</option>
<option value="homologene">HomoloGene</option>
<option value="medgen">MedGen</option>
<option value="mesh">MeSH</option>
<option value="ncbisearch">NCBI Web Site</option>
<option value="nlmcatalog">NLM Catalog</option>
<option value="nuccore">Nucleotide</option>
<option value="omim">OMIM</option>
<option value="pmc" data-ac_dict="pmc-search-autocomplete">
PMC</option>
<option value="popset">PopSet</option>
<option value="probe">Probe</option>
<option value="protein">Protein</option>
<option value="proteinclusters">Protein Clusters</option>
<option value="pcassay">PubChem BioAssay</option>
<option value="pccompound">PubChem Compound</option>
<option value="pcsubstance">PubChem Substance</option>
<option value="pubmed">PubMed</option>
<option value="pubmedhealth">PubMed Health</option>
<option value="snp">SNP</option>
<option value="sra">SRA</option>
<option value="structure">Structure</option>
<option value="taxonomy">Taxonomy</option>
<option value="toolkit">ToolKit</option>
<option value="toolkitall">ToolKitAll</option>
<option value="toolkitbook">ToolKitBook</option>
<option value="toolkitbookgh">ToolKitBookgh</option>
<option value="unigene">UniGene</option>
</optgroup>
</select>
<div class="nowrap"><label for="term" class="offscreen_noflow"
accesskey="/">Search term</label>
<div class="nowrap"><input type="text" name="term" id="term" title=
"Search PMC. Use up and down arrows to choose an item from the autocomplete."
value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" config=
"dictionary:'pmc-search-autocomplete',disableUrl:'NcbiSearchBarAutoComplCtrl'"
autocomplete="off" data-sbconfig=
"ds:'no',pjs:'no',afs:'yes'" /></div>
<button id="search" type="submit" class="button_search nowrap" cmd=
"go">Search</button></div>
</div>
</form>
<ul class="searchlinks inline_list">
<li><a href="/pmc/limits/">Limits</a></li>
<li><a href="/pmc/advanced/">Advanced</a></li>
<li><a href="/pmc/journals/">Journal list</a></li>
<li class="help"><a target="_blank" href=
"/books/NBK3825/">Help</a></li>
</ul>
</div>
</div>
<!--<component id="Page" label="headcontent"/>--></div>
<div class="content"><!-- site messages -->
<div class="container">
<div id="maincontent" class="content eight_col col">
<div class="navlink-box">
<ul class="page-breadcrumbs inline_list small">
<li class="journal-list"><a href="/pmc/journals/" class=
"navlink">Journal List</a></li>
<li class="archive-page"><a class="navlink" href=
"/pmc/journals/279/">Br J Clin Pharmacol</a></li>
<li class="issue-page"><a class="navlink" href=
"/pmc/issues/151556/">v.51(5); 2001 May</a></li>
<li class="accid">PMC2014477</li>
</ul>
</div>
<!-- Journal banner -->
<div class="pmc-page-banner whole_rhythm">
<div><img src="/corehtml/pmc/pmcgifs/logo-brjclinpharm.gif" alt=
"Logo of brjclinpharm" usemap="#logo-imagemap" /><map id=
"logo-imagemap" name="logo-imagemap">
<area alt="Link to Publisher's site" title=
"Link to Publisher's site" shape="default" coords="0,0,499,74"
href="http://www.blackwellpublishing.com/journal.asp?ref=0306-5251"
target="pmc_ext" ref=
"reftype=publisher&amp;article-id=2014477&amp;issue-id=151556&amp;journal-id=279&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal" />
</map></div>
</div>
<!--component id='MainPortlet' label='search-reference'/-->
<!-- Book content -->
<div class="">
<div class=
"hide-overflow article lit-style content pmc-wm slang-all page-box">
<!--main-content-->
<div class="jig-ncbiinpagenav" data-jigconfig=
"smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden'">
<div class="fm-sec half_rhythm no_top_margin">
<div class="fm-citation half_rhythm no_top_margin clearfix">
<div class="small">
<div class="inline_block eight_col va_top">
<div>
<div><span class="cit">Br J Clin Pharmacol. 2001 May; 51(5):
461–470.</span></div>
<div><span class="doi">doi:&nbsp; <a href=
"http://dx.doi.org/10.1046%2Fj.1365-2125.2001.01386.x" target=
"pmc_ext" ref=
"reftype=other&amp;article-id=2014477&amp;issue-id=151556&amp;journal-id=279&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI&amp;rendering-type=normal">
10.1046/j.1365-2125.2001.01386.x</a></span></div>
</div>
</div>
<div class=
"inline_block four_col va_top show-overflow align_right">
<div class="fm-citation-ids">
<div class="fm-citation-pmcid"><span class=
"fm-citation-ids-label">PMCID:</span> <span>PMC2014477</span></div>
</div>
</div>
</div>
</div>
<h1 class="content-title">Inhibitory effects of verapamil and
diltiazem on simvastatin metabolism in human liver microsomes</h1>
<div class="half_rhythm">
<div class="contrib-group fm-author"><a href=
"/pubmed/?term=Yeo%20KR%5Bauth%5D">Karen Rowland Yeo</a> and
<a href="/pubmed/?term=Yeo%20WW%5Bauth%5D">Wilfred W Yeo</a></div>
</div>
<div class="fm-panel small half_rhythm">
<div class="fm-authors-info fm-panel hide half_rhythm" id=
"id794449_ai" style="display:none">
<div class="fm-affl" lang="en">Section of Clinical Pharmacology
&amp; Therapeutics, University of Sheffield, Royal Hallamshire
Hospital, Glossop Road, Sheffield</div>
<div id="cor1"><em>Correspondence</em>: Dr K. Rowland Yeo, Clinical
Pharmacology &amp; Therapeutics, Division of Clinical Sciences
(CSUH), Floor L, Royal Hallamshire Hospital, Glossop Road,
Sheffield S10 2JF, UK. Tel.: 0114 2712776; Fax: 0114 2720275;
E-mail: <a href="mailto:dev@null" data-email=
"ku.ca.dleiffehs@oey.r.k" class=
"oemail">ku.ca.dleiffehs@oey.r.k</a></div>
</div>
<div class="togglers"><a href="#" class="pmctoggle" rid=
"id794449_ai">Author information <span>►</span></a> <a href="#"
class="pmctoggle" rid="id794449_an">Article notes
<span>►</span></a> <a href="#" class="pmctoggle" rid=
"id794449_cpl">Copyright and License information
<span>►</span></a></div>
<div class="fm-article-notes fm-panel hide half_rhythm" id=
"id794449_an" style="display:none">
<div class="fm-pubdate half_rhythm">Received 2000 Aug 23; Accepted
2001 Feb 5.</div>
</div>
<div class="fm-cpl-info fm-panel hide half_rhythm" id=
"id794449_cpl" style="display:none">
<div class="fm-copyright half_rhythm"><a href=
"/pmc/about/copyright.html">Copyright</a> © 2001 Blackwell Science
Ltd</div>
</div>
</div>
<div class="links-box fm-panel whole_rhythm">
<div class="small">
<div>This article has been <a href=
"/pmc/articles/PMC2014477/citedby/">cited by</a> other articles in
PMC.</div>
</div>
</div>
</div>
<div class="sec"></div>
<div id="__abstractid527266" lang="en" class="tsec sec">
<h2 class="head no_bottom_margin" id="__abstractid527266title">
Abstract</h2>
<!--article-meta-->
<div>
<div id="__sec1" class="sec sec-first">
<h3>Aims</h3>
<p id="__p1" class="p p-first-last">To determine the effects of
verapamil and diltiazem on simvastatin metabolism in human liver
microsomes and to compare their inhibitory potencies and CYP3A4
inactivation parameters with those reported previously for
mibefradil.</p>
</div>
<div id="__sec2" class="sec">
<h3>Methods</h3>
<p id="__p2" class="p p-first-last">Simvastatin metabolism was
investigated in human liver microsomes in the presence and absence
of verapamil or diltiazem (0.1–250 µ<span class=
"small-caps">m</span>). Kinetics of CYP3A4 inactivation by
verapamil and diltiazem were determined using testosterone as the
substrate.</p>
</div>
<div id="__sec3" class="sec">
<h3>Results</h3>
<p id="__p3" class="p p-first-last">When verapamil was coincubated
with simvastatin, I<em>C</em><sub>50</sub> values ranged from 23 to
26 µ<span class="small-caps">m</span> for all major metabolites.
The I<em>C</em><sub>50</sub> values ranged from 4.8 to 5.6
µ<span class="small-caps">m</span> on preincubation of verapamil
for 30 min in the presence of an NADPH-generating system.
Corresponding I<em>C</em><sub>50</sub> values for diltiazem ranged
from110–127 µ<span class="small-caps">m</span> and from 21–27
µ<span class="small-caps">m</span>, respectively. Verapamil and
diltiazem inhibited testosterone 6β-hydroxylation in a time- and
concentration-dependent manner, key features of mechanism-based
inactivation. Values for the inactivation parameters
<em>k</em><sub>inact</sub> and <em>K</em><sub>I</sub> were 0.15 ±
0.04 min<sup>−1</sup> (mean ± s.d.) and 2.9 ± 0.6 µ<span class=
"small-caps">m</span>, respectively, for verapamil and 0.07 ± 0.01
min<sup>−1</sup> and 3.3 ± 1.5 µ<span class="small-caps">m</span>,
respectively, for diltiazem.</p>
</div>
<div id="__sec4" class="sec sec-last">
<h3>Conclusions</h3>
<p id="__p4" class="p p-first-last">The I<em>C</em><sub>50</sub>
values for coincubation of verapamil and diltiazem were 46- and
220-fold higher, respectively, than those reported previously for
mibefradil, and 16- and 71-fold higher, respectively, for
preincubation. Thus, the results of this study suggest that
verapamil and diltiazem are less likely than mibefradil to cause
acute drug interactions with simvastatin <em>in vivo</em>. However,
verapamil and diltiazem are moderate mechanism-based inhibitors of
CYP3A4 and therefore may still cause significant inhibition of
simvastatin metabolism <em>in vivo</em> during chronic therapy.</p>
</div>
</div>
<div class="sec"><strong class="kwd-title">Keywords:</strong>
<span class="kwd-text">CYP3A4, diltiazem, verapamil, simvastatin,
interaction</span></div>
</div>
<div id="__sec5" class="tsec sec">
<h2 class="head no_bottom_margin" id="__sec5title">
Introduction</h2>
<p id="__p5" class="p p-first">The HMG-CoA reductase inhibitor
(statin) simvastatin is used extensively for treatment of
hypercholesterolaemia and has a major impact in the prevention of
coronary heart disease (CHD) [<a href="#b1" rid="b1" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_136999298">1</a>]. Simvastatin is an inactive lactone
pro-drug that is hydrolysed <em>in vivo</em> to simvastatin acid, a
potent competitive inhibitor of HMG-CoA reductase the rate-limiting
enzyme in cholesterol biosynthesis. The statin is generally well
tolerated and causes few subjective side-effects during chronic
treatment [<a href="#b1" rid="b1" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_136999316">1</a>]. Myopathy, which may present as
rhabdomyolysis, is a rare but serious side-effect of statin
treatment and occurs in 0.1% of patients treated with standard
doses of simvastatin or other HMG-CoA reductase inhibitors
[<a href="#b2" rid="b2" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_308637737">2</a>]. The risk of developing acute
rhabdomyolysis appears to increase considerably on addition of
drugs such as itraconazole [<a href="#b3" rid="b3" class=
" bibr popnode tag_hotlink tag_tooltip" id="__tag_136999290">3</a>]
and mibefradil [<a href="#b4" rid="b4" class=
" bibr popnode tag_hotlink tag_tooltip" id="__tag_136999297">4</a>,
<a href="#b5" rid="b5" class=
" bibr popnode tag_hotlink tag_tooltip" id="__tag_308637735">5</a>]
to the stable regimen of patients taking simvastatin. The onset of
rhabdomyolysis has been associated with dramatic increases in
plasma concentrations of HMG-CoA reductase inhibitory activity, due
to inhibition of the cytochrome P4503A4 (CYP3A4)-mediated
metabolism of simvastatin by the interacting drugs [<a href="#b6"
rid="b6" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_136999292">6</a>]. Results of an <em>in vitro</em> study
have confirmed that at therapeutic concentrations, mibefradil
inhibits the metabolism of simvastatin in human liver microsomes
and acts as a powerful mechanism-based inhibitor of CYP3A4 activity
[<a href="#b7" rid="b7" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_136999288">7</a>].</p>
<p id="__p6">Since the withdrawal of mibefradil from the market 2
years ago, there has been considerable debate regarding drug
interactions with simvastatin, particularly with respect to the
concomitant use of other calcium channel blockers [<a href="#b8"
rid="b8" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_136999293">8</a>, <a href="#b9" rid="b9" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_136999321">9</a>]. Many of these drugs are weak inhibitors
of CYP3A4 [<a href="#b10" rid="b10" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_136999318">10</a>], and diltazem and verapamil in
particular, have been shown to increase the plasma levels of
statins when used concurrently with simvastatin or the closely
related lovastatin [<a href="#b11" rid="b11" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_136999287">11</a>, <a href="#b12" rid="b12" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_136999296">12</a>]. Originally it was postulated that the
mechanism of interaction by diltiazem was competitive in nature
[<a href="#b13" rid="b13" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_136999313">13</a>], but a recent <em>in vitro</em> study has
demonstrated that diltiazem-mediated inhibition of midazolam
metabolism by CYP3A4 occurs primarily by metabolite intermediate
complex formation, which renders the enzyme inactive [<a href=
"#b14" rid="b14" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_308637731">14</a>]. Thus, the mechanism of CYP3A4 inhibition
by diltiazem appears to be similar to that observed with mibefradil
[<a href="#b7" rid="b7" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_136999301">7</a>]. It has also been reported that both
diltiazem and verapamil inhibit testosterone 6β-hydroxylation due
to metabolite-intermediate complexation with CYP3A [<a href="#b15"
rid="b15" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_308637736">15</a>]. The mechanism of inhibition was
characterized for both inhibitors but there were limited data on
the kinetics of inactivation.</p>
<p id="__p7" class="p p-last">In the present study the inhibitory
effects of verapamil and diltiazem on simvastatin metabolism in
human liver microsomes were investigated. In addition, the
inactivation kinetics of verapamil and diltiazem were determined
using incubation conditions described previously for the
characterization of CYP3A4 inhibition by mibefradil [<a href="#b7"
rid="b7" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_136999310">7</a>]. Thus, it was possible to compare directly
the inhibitory potencies and inactivation parameters of verapamil
and diltiazem with those reported for mibefradil, a known potent
inhibitor of CYP3A4 <em>in vitro</em> and <em>in vivo</em>
[<a href="#b7" rid="b7" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_136999289">7</a>].</p>
</div>
<div id="__sec6" class="tsec sec">
<h2 class="head no_bottom_margin" id="__sec6title">Methods</h2>
<div id="__sec7" class="sec sec-first">
<h3>Drugs and chemicals</h3>
<p id="__p8" class="p p-first-last">Simvastatin was provided by the
Merck Research Laboratories. Testosterone and its metabolite
testosterone 6β-hydroxylase, dilitazem and verapamil were purchased
from Sigma (London, UK). Glucose-6-phosphate (G6P) dehydrogenase
(grade II) and the disodium salts of G6P and NADP were purchased
from Boehringer Mannheim (Lewes, UK). Acetonitrile, ethyl acetate
and methanol were obtained from Rathburn (Walkerburn, UK). All
other reagents were of analytical grade and obtained from Merck
(Poole, UK).</p>
</div>
<div id="__sec8" class="sec">
<h3>Human liver microsomes</h3>
<p id="__p9" class="p p-first">Samples of human liver were obtained
from ‘normal’ tissue taken from carcinoma patients with the
approval of the Royal Hallamshire Hospital Ethics Committee and the
local Coroner. The 10 samples of human liver were subsequently
referred to as HL7, HL11, HL12, HL14, HL16, HL17, HL21, HL22, HL24
and HL25. There was no pathological evidence of hepatic disease in
any of the liver samples used. The donors of HL14 and HL22 were
female and the remaining donors were male. With the exception of
the donor of HL25 who was a black Caribbean, the donors were
Caucasian. None of the donors was a smoker. Drugs administered
prior to or during organ removal were fentanyl, atracurium,
thiopentone, morphine and droperidol.</p>
<p id="__p10" class="p p-last">Human liver microsomes were prepared
as described previously [<a href="#b16" rid="b16" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_136999305">16</a>] and stored at −80 °C as a suspension in
0.1 <span class="small-caps">m</span> potassium phosphate buffer
(pH 7.4) containing 30% (v/v) glycerol. Microsomal protein was
measured by the method of Lowry <em>et al.</em> [<a href="#b17"
rid="b17" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_136999300">17</a>] using bovine serum albumin as the
standard.</p>
</div>
<div id="__sec9" class="sec">
<h3>Effects of verapamil and diltiazem on simvastatin
metabolism</h3>
<p id="__p11" class="p p-first">Incubation mixtures comprised 100
µl microsomal suspension (equivalent to 0.05–0.25 mg microsomal
protein), inhibitors dissolved in 195 µl 1.15% KCl (w/v), 200 µl of
a NADPH-generating system dissolved in 0.2 <span class=
"small-caps">m</span> potassium phosphate buffer (pH 7.4) and 5
µmol simvastatin added in 5 µl acetone. The NADPH-generating system
consisted of 0.4 µmol NADP, 4 µmol G6P, 2 µmol MgCl<sub>2</sub> and
0.4 units of G6P-dehydrogenase. Verapamil or diltiazem was either
coincubated with simvastatin and microsomes before the reaction was
initiated with the NADPH-generating system or preincubated with
microsomes and the NADPH-generating system for 30 min at 37 °C
before addition of simvastatin. Control experiments were also
performed using preincubation and coincubation conditions to
determine simvastatin metabolism in the absence of any inhibitor.
Incubations were conducted at 37 °C and were terminated after 10
min by the addition of 0.5 ml acetone.</p>
<p id="__p12" class="p p-last">Preliminary experiments indicated
that the final substrate concentration of 10 µ<span class=
"small-caps">m</span> was comparable with the
<em>K</em><sub><em>m</em></sub> value of simvastatin and that the
formation of metabolites at this concentration was linear up to 0.5
mg protein ml<sup>−1</sup> and throughout the 10 min incubation
period. A range of concentrations (0.5–250 µ<span class=
"small-caps">m</span>) was used to investigate the effect of
verapamil and diltiazem on the formation of simvastatin
metabolites. Incubations were performed in triplicate at each
inhibitor concentration using microsomes prepared from HL7. The
experiment was repeated using microsomes from three different human
livers, at single inhibitor concentrations of 5 and 20
µ<span class="small-caps">m</span> for verapamil and diltiazem,
respectively (approximate I<em>C</em><sub>50</sub> values).</p>
</div>
<div id="__sec10" class="sec">
<h3>Effects of verapamil and diltiazem on CYP3A4 activity</h3>
<p id="__p13" class="p p-first">Testosterone 6β-hydroxylation was
used as a marker of CYP3A4 activity [<a href="#b18" rid="b18"
class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_136999315">18</a>]. Verapamil or diltiazem (0.5–250
µ<span class="small-caps">m</span>) were either coincubated with
testosterone and microsomes before the reaction was initiated with
the NADPH-generating system or preincubated with microsomes and the
NADPH-generating system for 30 min at 37 °C before the addition of
testosterone (25 µmol in 5 µl acetone). Both sets of incubations
were performed in the absence of inhibitor to determine control
testosterone 6β-hydroxylase activity. The incubations were
terminated after 10 min by the addition of 2 ml ethyl acetate. The
substrate concentration used was comparable with the
<em>K</em><sub><em>m</em></sub> value of testosterone (50
µ<span class="small-caps">m</span>). Incubations were performed in
triplicate at each inhibitor concentration using microsomes
prepared from HL7. To determine the time-dependent effect of CYP3A4
inactivation by the inhibitors, verapamil (2 µ<span class=
"small-caps">m</span>) and diltiazem (10 µ<span class=
"small-caps">m</span>) were preincubated in the presence of a
NADPH-generating system for various times ranging from 0 to 45 min.
The samples were then assayed for remaining CYP3A4 activity using
testosterone (50 µ<span class="small-caps">m</span>).</p>
<p id="__p14" class="p p-last">Microsomes prepared from 10
different human livers were preincubated with 1 µ<span class=
"small-caps">m</span> verapamil for 30 min in the presence of an
NADPH-generating system and were then assayed for remaining
testosterone 6β-hydroxylase activity. Incubations were carried out
in quadruplicate for each human liver. The experiment was repeated
using 1 µ<span class="small-caps">m</span> diltiazem.</p>
</div>
<div id="__sec11" class="sec">
<h3>Kinetics of CYP3A4 inactivation</h3>
<p id="__p15" class="p p-first-last">Studies on the kinetics of
CYP3A4 inactivation were performed using the testosterone
6β-hydroxylase assay at a substrate concentration of 250
µ<span class="small-caps">m</span>, in order to minimize
competitive inhibition by verapamil and diltiazem. Human liver
microsomes were preincubated with 0.5, 1, 2 and 5 µ<span class=
"small-caps">m</span> verapamil or 2, 5, 10 and 20 µ<span class=
"small-caps">m</span> diltiazem in the presence of an
NADPH-generating system for various times ranging from 0, 2, 5, 10,
15, 20 and 30 min at 37 °C. The incubation mixture was then assayed
for remaining CYP3A4 activity by the addition of testosterone (125
µmol in 5 µl acetone). The reaction was terminated after 10 min by
the addition of 2 ml ethyl acetate. Incubations were performed in
duplicate and the experiment was carried out using microsomes
prepared from three different human livers (HL7, HL12 and
HL16).</p>
</div>
<div id="__sec12" class="sec">
<h3><em>In vitro</em> metabolism of verapamil and diltiazem</h3>
<p id="__p16" class="p p-first-last">The disappearance of verapamil
and diltiazem in human liver microsomes was measured in order to
determine a partition ratio for CYP3A4 inactivation by each of the
inhibitors. Using the incubation conditions described previously
for simvastatin, verapamil (0.5 nmol) and diltiazem (2.5 nmol) were
incubated for various times ranging from 0 to 30 min. The reactions
were terminated by the addition of 200 µl acetone. Incubations were
carried out in duplicate using microsomes prepared from three
different livers (HL7, HL12 and HL16).</p>
</div>
<div id="__sec13" class="sec">
<h3>Analytical procedures</h3>
<p id="__p17" class="p p-first">Simvastatin and its metabolites
were assayed using modifications of methods described previously
[<a href="#b7" rid="b7" class=
" bibr popnode tag_hotlink tag_tooltip" id="__tag_136999306">7</a>,
<a href="#b19" rid="b19" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_308637730">19</a>]. Ethyl acetate (2 ml) was added to the
tubes containing the incubation mixture and the contents were
shaken for 15 min. After centrifugation at 900 <em>g</em> for 5
min, the organic phase was transferred to conical glass tubes and
evaporated to dryness under vacuum at 40 °C using a Buchler
vortex-evaporator (Baired and Tatlock, Romford, UK). The residue
was reconstituted in 200 µl mobile phase comprising
water/acetonitrile (45 : 55, v/v) containing 1% triethylamine
adjusted to pH 4 with orthophosphoric acid and subjected to
h.p.l.c. analysis. The samples were injected onto a Waters RCM
radial compression system containing a 0.8 × 10 cm NovaPak
C<sub>18</sub> cartridge, 4 µm particle size (Waters
Chromatography, Watford, UK) fitted with a Guard-Pak guard column
containing a C<sub>18</sub> insert (Waters). A Model 510
chromatography pump (Waters) was used for solvent delivery at a
flow rate of 2.5 ml min<sup>−1</sup>. The eluate was monitored
using a SF769 variable wavelength u.v. detector (Kratos,
Warrington, UK) set at 240 nm and 274 nm. Simvastatin is
metabolized to several products, including the two major
metabolites, 3′-hydroxy- and 6β-exomethylene-simvastatin [<a href=
"#b7" rid="b7" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_136999286">7</a>, <a href="#b18" rid="b18" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_136999320">18</a>]. Identification of the 6β-exomethylene
metabolite was made largely on the basis of its u.v. spectral
characteristics, i.e. λ<sub>max</sub> = 274 nm, and also by
comparison of its retention time with that reported previously
[<a href="#b18" rid="b18" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_136999319">18</a>]. The 3′-hydroxy-product was identified by
its retention time and also the fact that it was the main
metabolite observed at 240 nm using u.v. detection. The coefficient
of variation for assay of both metabolites was less than 5% at 10
nmol ml<sup>−1</sup> simvastatin.</p>
<p id="__p18">The same h.p.l.c. system including the NovaPak
C<sub>18</sub> column was used to measure the formation of
6β-hydroxytestosterone and disappearance of diltiazem and
verapamil. To assay 6β-hydroxytestosterone, 25 µl of a 10 µg
ml<sup>−1</sup> solution of 11β-hydroxytestosterone was added to
the tubes containing the incubation mixture and 2 ml ethyl acetate.
The samples were shaken for 15 min, prior to centrifugation at 900
<em>g</em> for 5 min. The organic phase was transferred to conical
glass tubes and evaporated to dryness under vacuum at 40 °C using a
Buchler vortex-evaporator. The samples were re-constituted in 200
µl mobile phase consisting of methanol/water (55 : 45, v/v) and
injected onto the h.p.l.c. system. The samples were eluted from the
column at a flow rate of 3 ml min<sup>−1</sup> and were monitored
by a u.v. detector set at 240 nm. The limit of determination of
6β-hydroxytestosterone was 30 pmol ml<sup>−1</sup>, and the
coefficient of variation at 160 pmol ml<sup>−1</sup> was less than
5%.</p>
<p id="__p19" class="p p-last">Verapamil and diltiazem were assayed
by centrifugation of the incubation samples at 900 <em>g</em> for 5
min and injecting the supernatants directly onto the h.p.l.c.
system. The samples were eluted from the column using a mobile
phase consisting of acetonitrile/water (28%: 72%, v/v) containing
1% triethylamine (adjusted to pH 3.5 with orthophosphoric acid).
The pump was set at a flow rate of 2.5 ml min<sup>−1</sup> and the
u.v. detector at 230 nm. The retention times of diltiazem and
verapamil were 5.5 and 10.7 min, respectively. At 5 nmol
ml<sup>−1</sup> diltiazem and at 1 nmol ml<sup>−1</sup> verapamil
the coefficients of variation for assay were 6% and 5%,
respectively.</p>
</div>
<div id="__sec14" class="sec sec-last">
<h3>Data analysis</h3>
<div id="__p20">
<p>The results were expressed as percentages of substrate consumed
or metabolites formed in the presence of verapamil or diltiazem
relative to the corresponding values obtained in the absence of any
inhibitor (control). I<em>C</em><sub>50</sub> values were
determined by a nonlinear regression analysis. The inactivation
parameters <em>k</em><sub>inact</sub> and <em>K</em><sub>I</sub>
were calculated according to the method of Silverman [<a href=
"#b20" rid="b20" class=" bibr popnode">20</a>]. The initial-rate
constant for inactivation (<em>k</em>, min<sup>−1</sup>) at each
inhibitor concentration was estimated from the initial slope of the
log-linear regression line of CYP3A4 activity remaining <em>vs</em>
the preincubation time profile. Initial estimates of the
inactivation parameters were then determined from the reciprocal
plot of rate constants for inactivation (1/<em>k</em>) <em>vs</em>
the respective inhibitor concentrations (1/I). These values were
used as first estimates for iterative nonlinear regression analysis
using the solver subprogram, which was implemented in Excel 97 to
calculate values for <em>k</em><sub>inact</sub> and
<em>K</em><sub>I</sub> according to the following equation:</p>
<div class="disp-formula">
<div class="f"><img src=
"/pmc/articles/PMC2014477/bin/bcp0051-0461-mu1.jpg" class=
"eq-image" alt="equation image" title="equation image" /></div>
</div>
<p>where <em>k</em> is the initial rate constant for inactivation
at the initial inhibitor concentration, I<sub>o</sub>;
<em>k</em><sub>inact</sub> is the maximum rate constant for
inactivation; and <em>K</em><sub>I</sub> is the inactivator
concentration which produces half the maximal rate of inactivation,
analogous to <em>K</em><sub><em>m</em></sub>. The partition ratio
was estimated from the initial disappearance rate constant of
verapamil and diltiazem relative to the initial rate constant for
inactivation of CYP3A4 activity at the same inhibitor
concentrations.</p>
</div>
<p id="__p21" class="p p-last">Comparisons of CYP3A4 activities and
percentage inhibition between control, verapamil and diltiazem
groups were performed using a non-parametric (Kruskal–Wallis)
one-way analysis of variance. Where this analysis indicated
significant differences (<em>P</em> &lt; 0.05) between groups,
individual comparisons were made using the Mann–Whitney test.</p>
</div>
</div>
<div id="__sec15" class="tsec sec">
<h2 class="head no_bottom_margin" id="__sec15title">Results</h2>
<div id="__sec16" class="sec sec-first">
<h3>Inhibitory effects of verapamil and diltiazem on simvastatin
metabolism</h3>
<p id="__p22" class="p p-first">Verapamil and diltiazem inhibited
simvastatin metabolism in a concentration-dependent manner
(<a href="/pmc/articles/PMC2014477/figure/fig01/" target="figure"
class="fig-table-link fig figpopup" rid-figpopup="fig01" rid-ob=
"ob-fig01" co-legend-rid="lgnd_fig01"><span>Figure
1a,b</span></a>). In experiments where verapamil was coincubated
with simvastatin, I<em>C</em><sub>50</sub> values ranged from 23 to
26 µ<span class="small-caps">m</span> for the formation of all
major metabolites (<a href="/pmc/articles/PMC2014477/figure/fig01/"
target="figure" class="fig-table-link fig figpopup" rid-figpopup=
"fig01" rid-ob="ob-fig01" co-legend-rid="lgnd_fig01"><span>Figure
1a</span></a>). When verapamil was preincubated for 30 min in the
presence of an NADPH-generating system the degree of inhibition
increased, the I<em>C</em><sub>50</sub> values ranging from 4.8 to
5.6 µ<span class="small-caps">m</span>. Corresponding
I<em>C</em><sub>50</sub> values for diltiazem ranged from110–127
µ<span class="small-caps">m</span> and from 21 to 27 µ<span class=
"small-caps">m</span>, respectively (<a href=
"/pmc/articles/PMC2014477/figure/fig01/" target="figure" class=
"fig-table-link fig figpopup" rid-figpopup="fig01" rid-ob=
"ob-fig01" co-legend-rid="lgnd_fig01"><span>Figure
1b</span></a>).</p>
<!--fig ft0--><!--fig mode=article f1-->
<div class="fig iconblock ten_col whole_rhythm clearfix" id="fig01"
co-legend-rid="lgnd_fig01"><a class="icnblk_img figpopup" href=
"/pmc/articles/PMC2014477/figure/fig01/" target="figure"
rid-figpopup="fig01" rid-ob="ob-fig01"><img src=
"/pmc/articles/PMC2014477/bin/bcp0051-0461-f1.gif" class=
"small-thumb" alt="Figure 1" title="Figure 1" src-large=
"/pmc/articles/PMC2014477/bin/bcp0051-0461-f1.jpg" /></a>
<div class="icnblk_cntnt" id="lgnd_fig01">
<div><a class="figpopup" href=
"/pmc/articles/PMC2014477/figure/fig01/" target="figure"
rid-figpopup="fig01" rid-ob="ob-fig01">Figure 1</a></div>
<!--caption a4-->
<div><span>Concentration-dependent inhibitory effects of (a)
verapamil and (b) diltiazem on formation of 3′-hydroxy-(▪) and
6β-exomethylene-simvastatin (•) in human liver microsomes.
Verapamil or diltiazem were either coincubated</span>
<strong>...</strong></div>
</div>
</div>
<p id="__p24" class="p">The experiment was repeated using
microsomes from four different human livers and single inhibitor
concentrations of 5 µ<span class="small-caps">m</span> verapamil
and 25 µ<span class="small-caps">m</span> diltiazem. These
concentrations were chosen because they approximated the
I<em>C</em><sub>50</sub> values determined in the initial
experiment. The degree of inhibition of 3′-hydroxy- and
6β-exomethylene-simvastatin formation was increased significantly
in microsomes from each liver by preincubation of verapamil and
dilitazem (<em>P</em> &lt; 0.05) (<a href=
"/pmc/articles/PMC2014477/figure/fig02/" target="figure" class=
"fig-table-link fig figpopup" rid-figpopup="fig02" rid-ob=
"ob-fig02" co-legend-rid="lgnd_fig02"><span>Figure
2a,b</span></a>).</p>
<!--fig ft0--><!--fig mode=article f1-->
<div class="fig iconblock ten_col whole_rhythm clearfix" id="fig02"
co-legend-rid="lgnd_fig02"><a class="icnblk_img figpopup" href=
"/pmc/articles/PMC2014477/figure/fig02/" target="figure"
rid-figpopup="fig02" rid-ob="ob-fig02"><img src=
"/pmc/articles/PMC2014477/bin/bcp0051-0461-f2.gif" class=
"small-thumb" alt="Figure 2" title="Figure 2" src-large=
"/pmc/articles/PMC2014477/bin/bcp0051-0461-f2.jpg" /></a>
<div class="icnblk_cntnt" id="lgnd_fig02">
<div><a class="figpopup" href=
"/pmc/articles/PMC2014477/figure/fig02/" target="figure"
rid-figpopup="fig02" rid-ob="ob-fig02">Figure 2</a></div>
<!--caption a4-->
<div><span>Inhibitory effects of (a) verapamil and (b) diltiazem on
simvastatin 3′-hydroxylation in microsomes from four different
human livers. Verapamil or diltiazem were either coincubated with
simvastatin and microsomes before the reaction was initiated</span>
<strong>...</strong></div>
</div>
</div>
</div>
<div id="__sec17" class="sec">
<h3>Inhibition of testosterone 6β-hydroxylase activity by verapamil
and diltiazem</h3>
<p id="__p26" class="p p-first">The inhibitory effects of verapamil
and diltiazem on testosterone 6β-hydroxylation were also
concentration dependent (<a href=
"/pmc/articles/PMC2014477/figure/fig03/" target="figure" class=
"fig-table-link fig figpopup" rid-figpopup="fig03" rid-ob=
"ob-fig03" co-legend-rid="lgnd_fig03"><span>Figure
3a,b</span></a>). As was observed with simvastatin,
I<em>C</em><sub>50</sub> values for preincubation were
approximately 5-fold lower than those obtained for coincubation.
I<em>C</em><sub>50</sub> values for inhibition of testosterone
6β-hydroxylation by preincubated verapamil and diltiazem were 27
and 122 µ<span class="small-caps">m</span>, respectively. In
coincubation experiments, the corresponding values were 3.1 and 26
µ<span class="small-caps">m</span>, respectively. These values were
comparable with those obtained when using simvastatin as the CYP3A4
substrate. The inhibitory effects of verapamil and diltiazem were
also found to be time-dependent (<a href=
"/pmc/articles/PMC2014477/figure/fig04/" target="figure" class=
"fig-table-link fig figpopup" rid-figpopup="fig04" rid-ob=
"ob-fig04" co-legend-rid="lgnd_fig04"><span>Figure
4a,b</span></a>).</p>
<!--fig ft0--><!--fig mode=article f1-->
<div class="fig iconblock ten_col whole_rhythm clearfix" id="fig03"
co-legend-rid="lgnd_fig03"><a class="icnblk_img figpopup" href=
"/pmc/articles/PMC2014477/figure/fig03/" target="figure"
rid-figpopup="fig03" rid-ob="ob-fig03"><img src=
"/pmc/articles/PMC2014477/bin/bcp0051-0461-f3.gif" class=
"small-thumb" alt="Figure 3" title="Figure 3" src-large=
"/pmc/articles/PMC2014477/bin/bcp0051-0461-f3.jpg" /></a>
<div class="icnblk_cntnt" id="lgnd_fig03">
<div><a class="figpopup" href=
"/pmc/articles/PMC2014477/figure/fig03/" target="figure"
rid-figpopup="fig03" rid-ob="ob-fig03">Figure 3</a></div>
<!--caption a4-->
<div><span>Concentration-dependent inhibitory effects of (a)
verapamil and (b) diltiazem on testosterone 6β-hydroxylation in
human liver microsomes. Verapamil or diltiazem were either
coincubated with testosterone (50 µ<span class=
"small-caps">m</span>) and microsomes before the</span>
<strong>...</strong></div>
</div>
</div>
<!--fig ft0--><!--fig mode=article f1-->
<div class="fig iconblock ten_col whole_rhythm clearfix" id="fig04"
co-legend-rid="lgnd_fig04"><a class="icnblk_img figpopup" href=
"/pmc/articles/PMC2014477/figure/fig04/" target="figure"
rid-figpopup="fig04" rid-ob="ob-fig04"><img src=
"/pmc/articles/PMC2014477/bin/bcp0051-0461-f4.gif" class=
"small-thumb" alt="Figure 4" title="Figure 4" src-large=
"/pmc/articles/PMC2014477/bin/bcp0051-0461-f4.jpg" /></a>
<div class="icnblk_cntnt" id="lgnd_fig04">
<div><a class="figpopup" href=
"/pmc/articles/PMC2014477/figure/fig04/" target="figure"
rid-figpopup="fig04" rid-ob="ob-fig04">Figure 4</a></div>
<!--caption a4-->
<div><span>Time-dependent loss of testosterone 6β-hydroxylase
activity in human liver microsomes after preincubation with (a)
verapamil and (b) dilltiazem. Microsomes were preincubated with 2
µ<span class="small-caps">m</span> verapamil or 10 µ<span class=
"small-caps">m</span> diltiazem for the designated</span>
<strong>...</strong></div>
</div>
</div>
<p id="__p29">With preincubation in the presence of an
NADPH-generating system, the inhibitory effects of 1 µ<span class=
"small-caps">m</span> verapamil and 1 µ<span class=
"small-caps">m</span> diltiazem on testosterone 6β-hydroxylation
were investigated in microsomes prepared from 10 different human
livers (<a href="/pmc/articles/PMC2014477/figure/fig05/" target=
"figure" class="fig-table-link fig figpopup" rid-figpopup="fig05"
rid-ob="ob-fig05" co-legend-rid="lgnd_fig05"><span>Figure
5a,b</span></a>). For each human liver, CYP3A4 activity was
decreased significantly by preincubation with either verapamil or
diltiazem (<em>P</em> &lt; 0.05). Mean testosterone 6β-hydroxylase
activity for all 10 human livers was reduced significantly from
1.22 ± 0.43–0.70 ± 0.27 nmol min<sup>−1</sup> mg<sup>−1</sup>
protein (<em>P</em> &lt; 0.05) after preincubation with verapamil.
Testosterone 6β-hydroxylase activity after preincubation with
diltiazem was reduced to 1.01 ± 0.39 nmol min<sup>−1</sup>
mg<sup>−1</sup> protein. This was not significantly different from
the control activity.</p>
<!--fig ft0--><!--fig mode=article f1-->
<div class="fig iconblock ten_col whole_rhythm clearfix" id="fig05"
co-legend-rid="lgnd_fig05"><a class="icnblk_img figpopup" href=
"/pmc/articles/PMC2014477/figure/fig05/" target="figure"
rid-figpopup="fig05" rid-ob="ob-fig05"><img src=
"/pmc/articles/PMC2014477/bin/bcp0051-0461-f5.gif" class=
"small-thumb" alt="Figure 5" title="Figure 5" src-large=
"/pmc/articles/PMC2014477/bin/bcp0051-0461-f5.jpg" /></a>
<div class="icnblk_cntnt" id="lgnd_fig05">
<div><a class="figpopup" href=
"/pmc/articles/PMC2014477/figure/fig05/" target="figure"
rid-figpopup="fig05" rid-ob="ob-fig05">Figure 5</a></div>
<!--caption a4-->
<div><span>Inhibition of testosterone 6β-hydroxylase activity in
microsomes prepared from 10 different human livers after
preincubation with (a) verapamil and (b) diltiazem. Microsomes were
preincubated with an NADPH generating system in the absence
(control)</span> <strong>...</strong></div>
</div>
</div>
<p id="__p31" class="p p-last">Absolute reduction in testosterone
6β-hydroxylase activity after preincubation with verapamil was
significantly correlated with baseline CYP3A4 activity
(<em>r</em><sub>s</sub> = 0.95; <em>P</em> &lt; 0.001). Thus, more
extensive inactivation was observed in microsomes with a higher
baseline activity (<a href="/pmc/articles/PMC2014477/figure/fig05/"
target="figure" class="fig-table-link fig figpopup" rid-figpopup=
"fig05" rid-ob="ob-fig05" co-legend-rid="lgnd_fig05"><span>Figure
5a</span></a>). On preincubation with diltiazem, absolute reduction
in CYP3A4 was not highly correlated with baseline activity
(<em>r</em><sub>s</sub> = 0.51).</p>
</div>
<div id="__sec18" class="sec sec-last">
<h3>Kinetics of CYP3A inactivation by verapamil and diltiazem</h3>
<p id="__p32" class="p p-first">Mean (± s.d., <em>n</em> = 3
livers) <em>k</em><sub>inact</sub> and <em>K</em><sub>I</sub>
values were 0.15 ± 0.04 min<sup>−1</sup> and 2.9 ± 0.6
µ<span class="small-caps">m</span>, respectively, for verapamil and
0.07 ± 0.01 min<sup>−1</sup> and 3.3 ± 1.5 µ<span class=
"small-caps">m</span>, respectively, for diltiazem (<a href=
"/pmc/articles/PMC2014477/table/tbl1/" target="true" class=
"fig-table-link table figpopup" rid-figpopup="tbl1" rid-ob=
"ob-tbl1" co-legend-rid=""><span>Table 1</span></a>, <a href=
"/pmc/articles/PMC2014477/figure/fig06/" target="figure" class=
"fig-table-link fig figpopup" rid-figpopup="fig06" rid-ob=
"ob-fig06" co-legend-rid="lgnd_fig06"><span>Figure 6</span></a>).
The potency of CYP3A4 inactivation by verapamil and diltiazem was
characterized further by calculation of the respective partition
ratios, defined as moles inhibitor metabolized per moles enzyme
inactivated. These values were found to be 10.3 ± 2.0 at 1
µ<span class="small-caps">m</span> verapamil and 19.7 ± 1.1 at 5
µ<span class="small-caps">m</span> diltiazem.</p>
<!--fig ft0--><!--fig mode=article f1-->
<div class="fig iconblock ten_col whole_rhythm clearfix" id="fig06"
co-legend-rid="lgnd_fig06"><a class="icnblk_img figpopup" href=
"/pmc/articles/PMC2014477/figure/fig06/" target="figure"
rid-figpopup="fig06" rid-ob="ob-fig06"><img src=
"/pmc/articles/PMC2014477/bin/bcp0051-0461-f6.gif" class=
"small-thumb" alt="Figure 6" title="Figure 6" src-large=
"/pmc/articles/PMC2014477/bin/bcp0051-0461-f6.jpg" /></a>
<div class="icnblk_cntnt" id="lgnd_fig06">
<div><a class="figpopup" href=
"/pmc/articles/PMC2014477/figure/fig06/" target="figure"
rid-figpopup="fig06" rid-ob="ob-fig06">Figure 6</a></div>
<!--caption a4-->
<div><span>Time- and concentration-dependent inactivation of human
liver microsomal testosterone 6β-hydroxylase activity by verapamil
(a). Concentrations of verapamil present in the preincubation
samples were 0 µ<span class="small-caps">m</span> (NADPH only) (×),
0.5 µ</span> <strong>...</strong></div>
</div>
</div>
<!--table ft1--><!--table-wrap mode=article t1-->
<div class="table-wrap iconblock ten_col whole_rhythm clearfix" id=
"tbl1"><a href="/pmc/articles/PMC2014477/table/tbl1/" target=
"table" rid-ob="ob-tbl1" rid-figpopup="tbl1" class=
"table img_link icnblk_img figpopup"><img alt="Table 1" title=
"Table 1" class="small-thumb" src=
"/pmc/articles/PMC2014477/table/tbl1/?report=thumb" src-large=
"/pmc/articles/PMC2014477/table/tbl1/?report=previmg" /></a>
<div class="icnblk_cntnt">
<div><a class="figpopup" href=
"/pmc/articles/PMC2014477/table/tbl1/" target="table" rid-figpopup=
"tbl1" rid-ob="ob-tbl1">Table 1</a></div>
<!--caption a4-->
<div><span>Inactivation parameters for verapamil and
diltiazem.</span></div>
</div>
</div>
</div>
</div>
<div id="__sec19" class="tsec sec">
<h2 class="head no_bottom_margin" id="__sec19title">Discussion</h2>
<p id="__p36" class="p p-first">The results of the present study
demonstrate that verapamil and diltiazem inhibit simvastatin
metabolism in human liver microsomes and that verapamil is the more
potent inhibitor. The I<em>C</em><sub>50</sub> values determined
from the coincubation experiments range from 23 to 26 µ<span class=
"small-caps">m</span>, for verapamil and from 110 to 127
µ<span class="small-caps">m</span> for diltiazem. The inhibitory
potency of each drug was increased approximately fivefold on
preincubation with human liver microsomes in the presence of an
NADPH-generating system. Thus, the metabolites of verapamil and
diltiazem are much more potent inhibitors of simvastatin metabolism
than the parent drugs. The fact that the I<em>C</em><sub>50</sub>
values were similar to those obtained when using the probe CYP3A4
substrate testosterone, confirms that verapamil and diltiazem
inhibit the CYP3A4-mediated metabolism of simvastatin.</p>
<p id="__p37">Testosterone 6β-hydroxylation was inhibited in a
time-and concentration-dependent manner by verapamil and diltiazem
showed a trend towards saturation of the inactivation rate. The
loss of catalytic activity was also dependent on the presence of an
NADPH generating system. The mean values of
<em>k</em><sub>inact</sub> and <em>K</em><sub>I</sub> for verapamil
were 0.15 ± 0.04 min<sup>−1</sup> and 2.9 ± 0.6 µ<span class=
"small-caps">m</span>, respectively. At 1 µ<span class=
"small-caps">m</span> verapamil, the partition ratio was estimated
to be 10.3 ± 20. The values of <em>k</em><sub>inact</sub>,
<em>K</em><sub>I</sub> and partition ratio for other
mechanism-based inhibitors of CYP3A4 that have been investigated
are: 1.6 min<sup>−1</sup>, 7.5 µ<span class="small-caps">m</span>
and 1.35, respectively, for L-754 394 [<a href="#b21" rid="b21"
class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_136999303">21</a>]; 0.4 min<sup>−1</sup>, 46 µ<span class=
"small-caps">m</span> and 9.0, respectively, for gestodene
[<a href="#b22" rid="b22" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_136999311">22</a>]; and 0.4 min<sup>−1</sup>, 2.3
µ<span class="small-caps">m</span> and 1.7, respectively, for
mibedrafil [<a href="#b7" rid="b7" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_136999299">7</a>]. Of the four drugs, verapamil has the
highest partition ratio. This indicates that a higher number of
molecules of verapamil have to be metabolized to inactivate the
same amount of enzyme as the other three drugs. Furthermore, the
<em>k</em><sub>inact</sub> value of verapamil is 2.7-fold lower
than that of mibefradil and gestodene, and 11-fold lower than that
of L-754 394. This suggests that verapamil has a lower efficiency
of inactivation and is a moderate mechanism-based inhibitor of
CYP3A4 compared with other drugs that have been studied so far. In
the present study, the mean <em>k</em><sub>inact</sub> and
<em>K</em><sub>I</sub> values for diltiazem were 0.07 ± 0.01
min<sup>−1</sup> and 3.3 ± 1.5 µ<span class="small-caps">m</span>,
respectively. At 5 µ<span class="small-caps">m</span> diltiazem,
the partition ratio was estimated to be 19.7 ± 1.1. These values
indicate that diltiazem is less efficient than verapamil as an
inactivator of CYP3A4. Jones <em>et al.</em> [<a href="#b14" rid=
"b14" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_308637728">14</a>] reported <em>k</em><sub>inact</sub> and
<em>K</em><sub>I</sub> values of 0.17 min<sup>−1</sup> and 2.2
µ<span class="small-caps">m</span>, respectively, for formation of
a metabolite-intermediate complex by diltiazem in microsomes from
human lymphoblastoid cells expressing CYP3A4(+ b<sub>5</sub>). The
2.4-fold lower <em>k</em><sub>inact</sub> value obtained in our
study may be due in part to the confounding presence of CYP3A5 in
human liver microsomes. This enzyme can metabolize testosterone and
also undergoes mechanism-based inactivation by diltiazem, but to a
lesser degree than CYP3A4 [<a href="#b14" rid="b14" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_308637734">14</a>]. It is also possible that other
cytochrome P450s may have contributed to the metabolism of
testosterone at the high substrate concentration of 250
µ<span class="small-caps">m</span>, which was used to determine
remaining CYP3A4 activity. The net result would be an
underestimation of the inactivation rate of CYP3A4. Ma <em>et
al.</em> [<a href="#b15" rid="b15" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_308637729">15</a>] reported <em>k</em><sub>inact</sub> and
<em>K</em><sub>I</sub> values of 0.03 min<sup>−1</sup> and 0.5
µ<span class="small-caps">m</span> for verapamil and 0.01
min<sup>−1</sup> and 0.5 µ<span class="small-caps">m</span> for
diltiazem. The methodology was not described in detail and
therefore it is not possible to explain the 5- to 10-fold
differences observed between their values and those obtained in our
study.</p>
<p id="__p38">Myopathy, which can rarely present as rhabdomyolysis,
is an uncommon but serious side-effect of statin treatment and
occurs in 0.1% of patients treated with standard doses of
simvastatin [<a href="#b1" rid="b1" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_136999294">1</a>]. The onset of acute rhabdomyolysis has
been associated with dramatic increases in plasma concentrations of
HMG-CoA reductase inhibitory activity, due to inhibition of
simvastatin metabolism by drugs such as itraconazole [<a href="#b3"
rid="b3" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_136999304">3</a>] or mibefradil [<a href="#b4" rid="b4"
class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_136999308">4</a>] that have been introduced to the dosing
regimen of simvastatin. The results of this study indicate that the
degree of inhibition of simvastatin metabolism by verapamil and
diltiazem is much lower than that observed with mibefradil, a known
potent inhibitor of CYP3A4 <em>in vitro</em> and <em>in vivo</em>
[<a href="#b4" rid="b4" class=
" bibr popnode tag_hotlink tag_tooltip" id="__tag_136999309">4</a>,
<a href="#b7" rid="b7" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_136999317">7</a>]. The I<em>C</em><sub>50</sub> values for
coincubation of verapamil and diltiazem are 46-and 220-fold higher,
respectively, than those reported for mibefradil, and 16- and
71-fold higher, respectively, for preincubation. These data suggest
that verapamil and diltiazem are much less likely than mibefradil
to cause acute drug interactions with simvastatin <em>in vivo</em>.
However, verapamil and diltiazem are moderate mechanism-based
inhibitors of CYP3A4 and may still cause significant inhibition of
CYP3A4-mediated metabolism of simvastatin <em>in vivo</em> during
chronic therapy. The enzyme is continuously being regenerated
<em>in vivo</em> and therefore the extent of CYP3A4 inactivation
will be dependent on the turnover rate of the enzyme, as well as
the inactivation parameters of the inhibitors. The fact that
verapamil and diltiazem are less efficient CYP3A4 inactivators than
mibefradil and other mechanism-based inhibitors studied so far,
further suggests that they are less likely to cause severe drug
interactions with simvastatin <em>in vivo</em>. To date, there have
been no reports of rhabdomyolysis induced by a
simvastatin–verapamil interaction and only one that was possibly
induced by a simvastatin–diltiazem interaction [<a href="#b1" rid=
"b1" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_136999291">1</a>].</p>
<p id="__p39">The effects of verapamil and diltiazem on the
pharmacokinetics of simvastatin and the closely related HMG-CoA
reductase inhibitor, lovastatin have been investigated in healthy
volunteers [<a href="#b11" rid="b11" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_136999314">11</a>, <a href="#b23" rid="b23" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_136999312">23</a>]. Verapamil caused a 4.6-fold increase in
the mean area under the concentration (AUC)-time curve of
simvastatin [<a href="#b23" rid="b23" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_136999302">23</a>] and diltiazem caused a fourfold increase
in the mean AUC of lovastatin [<a href="#b11" rid="b11" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_136999307">11</a>]. Verapamil (240 mg once daily) was
administered for 2 days prior to simvastatin dosing, whereas the
same dose of diltiazem was taken for 2 weeks prior to lovastatin
dosing. The degree of interaction is dependent on CYP3A4 activity
remaining after the period of administration of the mechanism-based
inhibitors, which in turn is dependent on final inhibitor
concentrations attained <em>in vivo</em>. Pretreatment with
verapamil for 2 days, may not have been long enough for the
inhibitor to evoke its maximum effect, thus resulting in an
underestimation of the magnitude of the interaction with
simvastatin. The increase in AUC of simvastatin caused by
pretreatment with verapamil ranged from 1.5- to 17-fold among the
12 volunteers and the diltiazem-induced increase in lovastatin AUC
ranged from 1.5- to 10.1-fold in the 10 subjects investigated. In
both studies, the magnitude of interaction for each subject was
dependent on their baseline hepatic CYP3A4 activity. Volunteers
with high baseline activity experienced greater magnitudes of
interaction whereas those with low baseline CYP3A4 activity
experienced lower levels of interaction. The net result was a
reduction in interindividual variability of simvastatin and
lovastatin AUC after pretreatment with verapamil and diltiazem,
respectively. The results of the present study reflect those
obtained <em>in vivo</em>. Absolute reduction in testosterone
6β-hydroxylase activity after preincubation with verapamil was
highly correlated with baseline CYP3A4 activity
(<em>r</em><sub>s</sub> = 0.95; <em>P</em> &lt; 0.001). For
diltiazem, the correlation was not significant but there was a
definite trend. Greater inactivation was observed in human liver
microsomes that had a higher baseline CYP3A4 activity. The net
result was a reduction in variability of baseline CYP3A4 activity
between livers (<a href="/pmc/articles/PMC2014477/figure/fig05/"
target="figure" class="fig-table-link fig figpopup" rid-figpopup=
"fig05" rid-ob="ob-fig05" co-legend-rid="lgnd_fig05"><span>Figure
5a,b</span></a>). This may have important clinical implications for
the cholesterol-lowering response to simvastatin in individuals who
are also taking verapamil or diltiazem. The results of a
retrospective study reported previously by our group demonstrated
that there was enhanced cholesterol reduction in patients who were
taking simvastatin and diltiazem concurrently, and the
interindividual variability in cholesterol-lowering response to
simvastatin was significantly lower for patients taking diltiazem
than for patients not taking diltiazem [<a href="#b24" rid="b24"
class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_136999295">24</a>]. To date, no studies have been reported
regarding the effect of verapamil on the cholesterol-lowering
response to simvastatin.</p>
<p id="__p40">Drug interactions with verapamil and diltiazem are
likely to occur with other HMGCoA reductase inhibitors that are
metabolized by CYP3A4, namely, atorvastatin and cerivastatin.
However, the magnitude of interaction of these two statins with
potent CYP3A4 inhibitors such as erythromycin, appears to be lower
than those observed with simvastatin and lovastatin [<a href="#b25"
rid="b25" class=" bibr popnode">25</a>, <a href="#b26" rid="b26"
class=" bibr popnode">26</a>]. Fluvastatin is metabolized primarily
by CYP2C8/9 and is therefore unlikely to have a clinically
significant interaction with either of the calcium channel blockers
[<a href="#b27" rid="b27" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_308637733">27</a>]. Similarly, metabolism is a minor route
of pravastatin elimination, and CYP3A4 does not contribute
significantly to the hepatic clearance of the drug [<a href="#b27"
rid="b27" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_308637732">27</a>].</p>
<p id="__p41" class="p p-last">According to the National Service
Framework [<a href="#b28" rid="b28" class=" bibr popnode">28</a>],
approximately 8% of the UK population require statin treatment for
secondary or primary prevention of coronary heart disease [<a href=
"#b29" rid="b29" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_136999285">29</a>]. Co-prescription of simvastatin with one
of the calcium channel blockers verapamil or diltiazem is likely to
occur commonly. The findings of this study demonstrate that
verapamil and diltiazem are not potent inhibitors of simvastatin
metabolism in human liver microsomes. However, verapamil and
diltiazem are moderate mechanism-based inhibitors of CYP3A4 and
therefore may still cause significant inhibition of simvastatin
metabolism <em>in vivo</em> during chronic therapy.</p>
</div>
<div id="__ackid192842" class="tsec sec">
<h2 class="head no_bottom_margin" id="__ackid192842title">
Acknowledgments</h2>
<div class="sec">
<p id="__p42">We thank Merck Research Laboratories for providing
the simvastatin. We also wish to thank Professor G.T. Tucker for
providing the human liver microsomes and laboratory facilities.</p>
</div>
</div>
<div id="__ref-listid192850" class="tsec sec">
<h2 class="head no_bottom_margin" id="__ref-listid192850title">
References</h2>
<div class="ref-list-sec sec" id="reference-list">
<div class="ref-cit-blk half_rhythm" id="b1">1. <span class=
"citation">Scandinavian Simvastatin Survival Study Group.
Randomised trial of cholesterol lowering in 4444 patients with
heart disease: the Scandinavian Simvastatin Survival Study (4S)
<span><span class="ref-journal">Lancet.</span> 1994;<span class=
"ref-vol">344</span>:1383–1389.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/7968073" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2014477&amp;issue-id=151556&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b2">2. <span class=
"citation">Blum CB. Comparison of four inhibitors of 3-hydroxy-
3-methylglutaryl-coenzyme A reductase. <span><span class=
"ref-journal">Am J Cardiol.</span> 1994;<span class=
"ref-vol">73</span>:3D–11D.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/8198021" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2014477&amp;issue-id=151556&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b3">3. <span class=
"citation">Segaert MF, De Soete C, Vandewiele I, Verbanck J.
Drug-interaction-induced rhabdomyolysis. <span><span class=
"ref-journal">Nephrol Dial Transplant.</span> 1996;<span class=
"ref-vol">11</span>:1846–1847.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/8918636" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2014477&amp;issue-id=151556&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b4">4. <span class=
"citation">Schmassmann-Suhijar D, Bullingham R, Gasser R, Schmutz
J, Haefeli WE. Rhabdomyolysis due to interaction of simvastatin
with mibefradil. <span><span class="ref-journal">Lancet.</span>
1998;<span class="ref-vol">351</span>:1929.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/9654265" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2014477&amp;issue-id=151556&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b5">5. <span class=
"citation">Roche. FDA announce new drug-interacting warnings for
mibefradil. <span><span class="ref-journal">Am J Health-Syst
Pharm.</span> 1998;<span class="ref-vol">55</span>:210.</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/9492249" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=2014477&amp;issue-id=151556&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b6">6. <span class=
"citation">Prueksaritanont T, Gorham LM, Bennett MA, et al. <em>In
vitro</em> metabolism of simvastatin in humans – identification of
metabolising enzymes and effect of the drug on hepatic P450s.
<span><span class="ref-journal">Drug Metab Dispos.</span>
1997;<span class="ref-vol">25</span>:1191–1199.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/9321523" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2014477&amp;issue-id=151556&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b7">7. <span class=
"citation">Prueksaritanont T, Ma B, Tang C, et al. Metabolic
interactions between mibefradil and HMG-CoA reductase inhibitors:
an in vitro investigation with human liver preparations.
<span><span class="ref-journal">Br J Clin Pharmacol.</span>
1999;<span class="ref-vol">47</span>:291–298.</span> <span class=
"nowrap ref pmc">[<a class="int-reflink" href=
"/pmc/articles/PMC2014217/">PMC free article</a>]</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/10215754" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=2014477&amp;issue-id=151556&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b8">8. <span class=
"citation">Gruer PJK, Vega JM, Mercuri MF, Dobrinska MR, Tobert JA.
Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin.
<span><span class="ref-journal">Am J Cardiol.</span>
1999;<span class="ref-vol">84</span>:811–815.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/10513779" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=2014477&amp;issue-id=151556&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b9">9. <span class=
"citation">Neuvonen PJ, Kantola T, Kivisto KT. Calcium channel
blocker–simvastatin interaction. <span><span class=
"ref-journal">Clin Pharmacol Ther.</span> 1999;<span class=
"ref-vol">65</span>:583.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/10340925" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=2014477&amp;issue-id=151556&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b10">10. <span class=
"citation">Thummel KE, Wilkinson GR. <em>In vitro</em> and <em>in
vivo</em> drug interactions involving human CYP3A.
<span><span class="ref-journal">Ann Rev Pharmacol Toxicol.</span>
1998;<span class="ref-vol">38</span>:389–430.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/9597161" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2014477&amp;issue-id=151556&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b11">11. <span class=
"citation">Azie NE, Brater DC, Becker PA, Jones DR, Hall SD. The
interaction of diltiazem with lovastatin and pravastatin.
<span><span class="ref-journal">Clin Pharmacol Ther.</span>
1998;<span class="ref-vol">64</span>:369–377.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/9797793" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2014477&amp;issue-id=151556&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b12">12. <span class=
"citation">Kantola T, Kivisto K, Neuvonen P. Erythromycin and
verapamil considerably increase simvastatin and simvastatin acid
concentrations. <span><span class="ref-journal">Clin Pharmacol
Ther.</span> 1998;<span class="ref-vol">64</span>:177–182.</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/9728898" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=2014477&amp;issue-id=151556&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b13">13. <span class=
"citation">Sutton D, Butler AM, Nadin L, Murray M. Role of CYP3A4
in human hepatic diltiazem N-demethylation: inhibition of CYP3A4
activity by oxidised diltiazem metabolites. <span><span class=
"ref-journal">J Pharmacol Exp Ther.</span> 1997;<span class=
"ref-vol">282</span>:294–300.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/9223567" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2014477&amp;issue-id=151556&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b14">14. <span class=
"citation">Jones DR, Gorski JC, Hamman MA, Mayhew BS, Rider S, Hall
SD. Diltiazem inhibition of cytochrome P450, 3A activity is due to
metabolite–intermediate complex formation. <span><span class=
"ref-journal">J Pharmacol Exp Ther.</span> 1999;<span class=
"ref-vol">28</span>:294–300.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/10454485" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=2014477&amp;issue-id=151556&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b15">15. <span class=
"citation">Ma B, Prueksaritanont T, Lin JH. Drug interactions with
calcium channel blockers: possible involvement of
metabolite-intermediate complexation with CYP3A. <span><span class=
"ref-journal">Drug Metab Disp.</span> 2000;<span class=
"ref-vol">28</span>:125–130.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/10640508" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=2014477&amp;issue-id=151556&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b16">16. <span class=
"citation">Otton SV, Crewe HK, Lennard MS, Tucker GT, Woods HF. Use
of quinidine inhibition to define the role of the
sparteine/debrisoquine cytochrome P450 in metoprolol oxidation in
human liver microsomes. <span><span class="ref-journal">J Pharmacol
Exp Ther.</span> 1988;<span class=
"ref-vol">247</span>:242–247.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/3171974" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2014477&amp;issue-id=151556&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b17">17. <span class=
"citation">Lowry OH, Roseburgh NJ, Farr AL, Randall RJ. Protein
measurement with the folin phenol reagent. <span><span class=
"ref-journal">J Biol Chem.</span> 1951;<span class=
"ref-vol">193</span>:265–275.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/14907713" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=2014477&amp;issue-id=151556&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b18">18. <span class=
"citation">He Kan Woolf T, Hollenberg PF. Mechanism-based
inactivation of cytochrome P4503A4 by mifepristone (RU486)
<span><span class="ref-journal">J Pharmacol Exp Ther.</span>
1999;<span class="ref-vol">288</span>:791–797.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/9918590" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2014477&amp;issue-id=151556&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b19">19. <span class=
"citation">Vickers S, Duncan CA, Vyas KP, et al. <em>In vitro</em>
and <em>in vivo</em> biotransformation of simvastatin, an
inhibitor. <span><span class="ref-journal">Of HMG-Coa Reductase
Drug Metab Disp.</span> 1990;<span class=
"ref-vol">18</span>:138–145.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/1976071" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2014477&amp;issue-id=151556&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b20">20. <span class=
"citation">Silverman RB. <span class="ref-journal">Mechanism-Based
Enzyme Inactivation: Chemistry and Enzymology <em>Boca
Raton</em>.</span> Vol. 1. Boca Raton: CRC Press; 1988. pp.
3–15.</span></div>
<div class="ref-cit-blk half_rhythm" id="b21">21. <span class=
"citation">Chiba M, Nishime JA, Lin JH. Potent and selective
inactivation of human liver microsomal cytochrome P450 isoforms by
L-754,394, an investigational human immune deficiency virus
protease inhibitor. <span><span class="ref-journal">J Pharmacol Exp
Ther.</span> 1995;<span class=
"ref-vol">275</span>:1527–1534.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/8531125" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2014477&amp;issue-id=151556&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b22">22. <span class=
"citation">Guengerich F. Mechanism-based inactivation of human
liver microsomal cytochrome P450 III A4 by gestodene.
<span><span class="ref-journal">Chem Res Toxicol.</span>
1990;<span class="ref-vol">3</span>:363–371.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/2133086" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2014477&amp;issue-id=151556&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b23">23. <span class=
"citation">Kantola T, Kivisto KT, Neuvonen PJ. Erythromycin and
verapamil considerably increase serum simvastatin and simvastatin
acid concentrations. <span><span class="ref-journal">Clin Pharmacol
Ther.</span> 1998;<span class="ref-vol">64</span>:177–182.</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/9728898" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=2014477&amp;issue-id=151556&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b24">24. <span class=
"citation">Rowland Yeo K, Yeo WW, Wallis EJ, Ramsay LE. Enhanced
cholesterol reduction by simvastatin in diltiazem-treated patients.
<span><span class="ref-journal">Br J Clin Pharmacol.</span>
1999;<span class="ref-vol">48</span>:610–615.</span> <span class=
"nowrap ref pmc">[<a class="int-reflink" href=
"/pmc/articles/PMC2014381/">PMC free article</a>]</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/10583033" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=2014477&amp;issue-id=151556&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b25">25. <span class=
"citation">Yang BB, Siedlek PH, Smithers JA, Sedman AJ, Stern RH.
Atorvastatin pharmacokinetic interactions with other CYP3A4
substrates: erythromycin and ethinyl estradiol. <span><span class=
"ref-journal">Pharmacol Res.</span> 1996;<span class=
"ref-vol">13</span>(Suppl 9):S437.</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b26">26. <span class=
"citation">Ochmann K, Mueck W, Unger S, Kuhlmann J. Influence of
erythromycin pre- and co-treatment on the single dose
pharmacokinetics of cerivastatin. <span><span class=
"ref-journal">Eur J Clin Pharmacol.</span> 1997;<span class=
"ref-vol">52</span>(Suppl):A139.</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b27">27. <span class=
"citation">Desager JP, Horsmans Y. Clinical pharmacokinetics of
3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors.
<span><span class="ref-journal">Clin Pharmacokin.</span>
1996;<span class="ref-vol">31</span>:348–371.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/9118584" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2014477&amp;issue-id=151556&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b28">28. <span class=
"citation">Department of Health. London: DoH; 2000. National
service framework for coronary heart disease. Modern standards and
servic models.</span></div>
<div class="ref-cit-blk half_rhythm" id="b29">29. <span class=
"citation">Haq IUL, Ramsay LE, Pickin DM, Yeo WW, Jackson PR, Payne
JN. Lipid-lowering for prevention of coronary heart disease: what
policy now? <span><span class="ref-journal">Clin Sci.</span>
1996;<span class="ref-vol">91</span>:399–413.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/8983865" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2014477&amp;issue-id=151556&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
</div>
</div>
</div>
<!--post-content-->
<hr class="whole_rhythm no_bottom_margin" />
<div class="courtesy-note no_margin small">Articles from
<span class="acknowledgment-journal-title">British Journal of
Clinical Pharmacology</span> are provided here courtesy of
<strong>British Pharmacological Society</strong></div>
</div>
</div>
<!-- Book content --></div>
<div id="rightcolumn" class="four_col col last">
<!-- Custom content above discovery portlets -->
<div class="col6"></div>
<div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi=
"http://www.w3.org/2001/XMLSchema-instance">
<div class="try-button"><a href=
"/pmc/articles/PMC2014477/?report=reader"><img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/3838809"
alt="PubReader format: click here to try" /></a></div>
<div class="format-menu">
<h2>Formats:</h2>
<ul>
<li class="selected">Article</li>
<li style="list-style: none">|</li>
<li><a href=
"/pmc/articles/PMC2014477/?report=reader">PubReader</a></li>
<li style="list-style: none">|</li>
<li class="epub-link"><a href="/pmc/articles/PMC2014477/epub/">ePub
(beta)</a></li>
<li style="list-style: none">|</li>
<li><a href="/pmc/articles/PMC2014477/pdf/bcp0051-0461.pdf">PDF
(204K)</a></li>
<li style="list-style: none">|</li>
<li><a href="#" data-citationid="PMC2014477" class=
"citationexporter ctxp">Citation</a></li>
</ul>
</div>
</div>
<div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi=
"http://www.w3.org/2001/XMLSchema-instance" class="share-buttons">
<h2>Share</h2>
<ul>
<li class="facebook"><a href=
"https://www.facebook.com/sharer/sharer.php?u=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2014477%2F">
<img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/4047626"
alt="Share on Facebook" /> Facebook</a></li>
<li class="twitter"><a href=
"https://twitter.com/intent/tweet?url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2014477%2F&amp;text=Inhibitory%20effects%20of%20verapamil%20and%20diltiazem%20on%20simvastatin%20metabolism%20in%20human%20liver%20microsomes">
<img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/4047627"
alt="Share on Twitter" /> Twitter</a></li>
<li class="gplus"><a href=
"https://plus.google.com/share?url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2014477%2F">
<img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/4047628"
alt="Share on Google Plus" /> Google+</a></li>
</ul>
</div>
<div id="ajax-portlets" data-pmid="11422004" data-aiid="2014477"
data-aid="2014477" data-iid="151556" data-domainid="279"
data-domain="brjclinpharm" data-accid="PMC2014477" data-md5=
"5eb186224964278b4b0ae1a258849c05"></div>
<!-- Custom content below discovery portlets -->
<div class="col7"></div>
</div>
</div>
<!-- Custom content after all -->
<div class="col8"></div>
<div class="col9"></div>
<script src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js">
</script> <script>
<![CDATA[
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
]]>
</script>
<div id="body-link-poppers"></div>
</div>
<div class="bottom">
<div id="NCBIFooter_dynamic">
<div class="breadcrumbs">You are here: <span id=
"breadcrumb_text"><a href="/guide/">NCBI</a> &gt; <a href=
"http://www.ncbi.nlm.nih.gov/guide/literature/">Literature</a> &gt;
<a href="http://www.ncbi.nlm.nih.gov/pmc/">PubMed Central
(PMC)</a></span></div>
<a id="help-desk-link" class="help_desk jig-ncbihelpwindow" target=
"_blank" href=
"/sites/ehelp?&amp;Ncbi_App=pmc&amp;Db=pmc&amp;Page=literature&amp;Snapshot=/projects/PMC/PMCViewer@4.35&amp;Time=2016-04-01T09:54:11-04:00&amp;Host=ptpmc202">Write
to the Help Desk</a></div>
<div class="footer" id="footer">
<div class="subfooter"></div>
<script type="text/javascript" src=
"/portal/portal3rc.fcgi/static/js/preloaderWidget.js">
</script>
<div id="external-disclaimer" class="offscreen_noflow">External
link. Please review our <a href=
"http://www.nlm.nih.gov/privacy.html">privacy policy</a>.</div>
<div id="ncbifooter" class="contact_info">
<div id="footer-contents-right">
<div id="nlm_thumb_logo"><a href="http://www.nlm.nih.gov" title=
"NLM">NLM</a></div>
<div id="nih_thumb_logo"><a href="http://www.nih.gov" title=
"NIH">NIH</a></div>
<div id="hhs_thumb_logo"><a href="http://www.dhhs.gov" title=
"DHHS">DHHS</a></div>
<div id="usagov_thumb_logo"><a href="http://www.usa.gov" title=
"USA.gov">USA.gov</a></div>
</div>
<div id="footer-contents-left"><a href=
"/About/disclaimer.html">Copyright</a> | <a href=
"/About/disclaimer.html#disclaimer">Disclaimer</a> | <a href=
"http://www.nlm.nih.gov/privacy.html" class="newdomain">Privacy</a>
| <a href="/guide/browsers/">Browsers</a> | <a href=
"http://www.nlm.nih.gov/accessibility.html">Accessibility</a> |
<a href="/About/glance/contact_info.html">Contact</a>
<p class="address vcard"><span class="url"><a class=
"fn url newdomain" href="http://www.ncbi.nlm.nih.gov">National
Center for Biotechnology Information</a>,</span> <span class=
"org url"><a href="http://www.nlm.nih.gov/">U.S. National Library
of Medicine</a></span> <span class="adr"><span class=
"street-address">8600 Rockville Pike</span>, <span class=
"locality">Bethesda</span> <span class="region">MD</span>,
<span class="postal-code">20894</span> <span class=
"country-name">USA</span></span></p>
</div>
</div>
<script type="text/javascript" src=
"/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1">
</script> <script type="text/javascript" src=
"/portal/portal3rc.fcgi/static/js/hfjs2.js">
</script></div>
</div>
</div>
<!--/.page--></div>
<!--/.wrap--></div>
<!-- /.twelve_col --></div>
<!-- /.grid -->
 <!-- BESelector tab -->
 <noscript><img alt="statistics" src=
"/stat?jsdisabled=true&amp;ncbi_db=pmc&amp;ncbi_pdid=article&amp;ncbi_acc=&amp;ncbi_domain=brjclinpharm&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/articles/PMC2014477/&amp;ncbi_app=pmc" />
</noscript> <!-- usually for JS scripts at page bottom -->
 <!--<component id="PageFixtures" label="styles"></component>-->
 
<!-- F4FC4E326FE7D821_0127SID /projects/PMC/PMCViewer@4.35 ptpmc202 v4.1.r480124 Mon, Sep 28 2015 02:46:19 -->
 <script type="text/javascript" src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/js/3879255/3728312/3818874/3821238/4064716/4072593/4064449/3921943/4070217/4065628.js"
snapshot="pmc">
</script>
</body>
</html>
